Company / Cost of Revenue
Serina Therapeutics, Inc. Cost of Revenue History
FY2018-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$40.0K
FY2023
5-year range
$13.0K / $40.0K
FY2019-FY2023
Trend
+207.7%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue changed +208% YoY in FY2023, a notable deviation from the 4-year average annual change of +13%.
Based on SEC 10-K filings.
$40,000 in FY2023 with a 5-year CAGR of -35.7%.
Increased from $19,000 to $40,000 over the past 2 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -45.3%
- 5-Year CAGR
- -35.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -35.7%, indicating a declining trend.
- In FY2023, cost of revenue increased 207.7% year-over-year.
- Peak cost of revenue was recorded in FY2018.
- Lowest cost of revenue in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $40.0K | +207.7% |
| FY2022 | $13.0K | -31.6% |
| FY2021 | $19.0K | -92.2% |
| FY2020 | $244.0K | -33.0% |
| FY2018 | $364.0K | - |
As of FY2023 · SEC 10-K Annual Filings · Updated Jun 24, 2026